|
gptkbp:instanceOf
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AB10
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Lexapro
gptkb:Cipralex
gptkb:Seroplex
|
|
gptkbp:CASNumber
|
128196-01-0
|
|
gptkbp:chemicalFormula
|
C20H21FN2O
|
|
gptkbp:contraindication
|
concomitant use with MAOIs
hypersensitivity to escitalopram
|
|
gptkbp:developedBy
|
gptkb:Lundbeck
gptkb:Forest_Laboratories
|
|
gptkbp:eliminationHalfLife
|
27-32 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasEnantiomer
|
gptkb:citalopram
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
escitalopram
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:MedlinePlusID
|
a603005
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
gptkb:CYP2C19
gptkb:CYP2D6
gptkb:CYP3A4
liver
|
|
gptkbp:molecularWeight
|
324.4 g/mol
|
|
gptkbp:notRecommendedFor
|
children under 12
|
|
gptkbp:pregnancyCategory
|
C
C (US)
|
|
gptkbp:prescribes
|
adults
adolescents (in some countries)
|
|
gptkbp:proteinBinding
|
56%
|
|
gptkbp:PubChem_CID
|
146570
DB01175
|
|
gptkbp:relatedTo
|
gptkb:citalopram
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts
QT prolongation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
insomnia
drowsiness
dry mouth
sexual dysfunction
increased sweating
|
|
gptkbp:UNII
|
4ZWB8V8Y2I
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:citalopram
gptkb:SSRIs
gptkb:selective_serotonin_reuptake_inhibitors
|
|
gptkbp:bfsLayer
|
6
|